Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work (not exceeding fifteen (15) words), full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNxxxxxxxx (where xxxxxxxxx represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTxxxxxxxx (where xxxxxxxxx represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

**Submission of Manuscripts.** Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

**Reprints.** Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Hypofractionated Stereotactic Radiotherapy and Radiosurgery for the Treatment of Patients with Radioresistant Brain Metastases. M. SCORSETTI, A. FACOETTI, P. NAVARRIA, M. BIGNARDI, M. DE SANTIS, S.A. NINONE, P. LATTUADA, G. URSO, S. VIGORITO, P. MANCOSU, M. DEL VECCHIO (Rozzano; Pavia; Milan, Italy) ........................................................ 4259


The Efficacy of Endoscopic Submucosal Dissection Compared with Modified Endoscopic Aspiration Mucosectomy by Assessing the Short-term Therapeutic Results for Differentiated Mucosal Gastric Cancer. T. KATSUBE, M. MURAYAMA, N. ISOHATA, S. ASAKA, K. YAMAGUCHI, K. KUHARA, S. KONNO, T. SHIMAKAWA, Y. NARITAKA, K. OGAWA (Tokyo, Japan) .............................................................. 4271

A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma. F. ZUSTOVICH, G. LOMBARDI, A. DELLA PUPPA, A. ROTILIO, R. SCIENZA, D. PASTORELLI (Padova, Italy) ................................................................................. 4275

The Follow-up of Patients with Non-muscle-invasive Bladder Cancer by Urine Cytology, Abdominal Ultrasound and Urine CYFRA 21-1: A Pilot Study. B. NISMAN, V. YUTKIN, T. PERETZ, A. SHAPIRO, V. BARAK, D. PODE (Jerusalem, Israel) ................................................................. 4281


Prognostic Value of Serum Tumor Antigen CA19-9 After Curative Resection of Colorectal Cancer. I. J. PARK, G.-S. CHOI, S.H. JUN (Daegu, South Korea) .......................................................................................................................................................... 4303

Retrospective Study of Venous Thromboembolic and Intracerebral Hemorrhagic Events in Glioblastoma Patients. E. PAN, J.S. TSAI, S.B. MITCHELL (Tampa; Orlando, FL; Los Angeles, CA, USA) ........................................ 4309

Errata .................................................................................................................................................. 4315

* Reviews (pages 3759, 3833, 4107)

Diverse Prognostic Roles of Akt Isoforms, PTEN and PI3K in Tumor Epithelial Cells and Stromal Compartment in Non-small Cell Lung Cancer. S. AL-SAAD, T. DONNEM, K. AL-SHIBLI, M. PERSSON, R.M. BREMNES, L.-T. BUSUND (Tromsø; Bodø, Norway) ........................................................................................................... 4175


Single-institution Outcome of High-dose Interleukin-2 (HD IL-2) Therapy for Metastatic Melanoma and Analysis of Favorable Response in Brain Metastases. S. POWELL, A.Z. DUDEK (Minneapolis, MN, USA) ........................................... 4189

Pegylated Liposomal Doxorubicin and Carboplatin in Late-relapsing Ovarian Cancer: A GINECO Group Phase II Trial. B. WEBER, A. LORTHOLARY, F. MAYER, H. BOURGOIS, H. ORFEUVRE, M. COMBE, C. PLATINI, J. CRETIN, D. FRIC, D. PARAISO, E. PUJADE-LAURAINE (Vandoeuvre-les-Nancy; Dijon; Le Mans; Nîmes; Montargis; Paris, France) ........................................................................................................... 4195

Altered p53 and pRb Expression Is Predictive of Response to BCG Treatment in T1G3 Bladder Cancer. L. CORMIO, I. TOLVE, P. ANNESE, A. SARACINO, R. ZAMPARESE, F. SANGUEDOLCE, P. BUFO, M. BATTAGLIA, F.P. SELVAGGI, G. CARRIERI (Foggia; Bari, Italy) ........................................................................................................... 4201

Clinical Outcome of Tailored Adjuvant Postoperative Chemoradiotherapy in IB FIGO Stage Cervical Cancer. M.G. FABRINI, A. GADDUCCI, F. PERRONE, S. COSIO, C. LALISCIA, F. PASQUALETTI, S. GRESPI, L. CIONINI (Pisa, Italy) ........................................................................................................... 4205

Induction Chemotherapy with Docetaxel, 5-FU and CDDP (DFP) for Advanced Gastric Cancer. K. YAMAMOTO, Y. FUJIWARA, T. NISHIDA, S. TAKIGUCHI, K. NAKAJIMA, H. MIYATA, M. YAMASAKI, M. MORI, Y. DOKI (Osaka, Japan) ........................................................................................................... 4211

Treatment after the Failure of Gefitinib in Patients with Advanced or Recurrent Non-small Cell Lung Cancer. R. MARUYAMA, H. WATAYA, T. SETO, Y. ICHINOSE (Fukuoka, Japan) ........................................................................................................... 4217


Elevated Malondialdehyde Correlates with the Extent of Primary Tumor and Predicts Poor Prognosis of Oropharyngeal Cancer. R. SALZMAN, L. PÁCAL, J. TOMANDL, K. KAŇKOVA, E. TOTHOVÁ, B. GÁL, R. KOSTŘICA, P. SALZMAN (Brno, Czech Republic; Rochester, NY, USA) ........................................................................................................... 4227

An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma. M. KROPFF, J. KIENAST, G. BISPING, W.E. BERDEL, B. GASCHLER-MARKEFSKI, P. STOPFER, M. STEFANIC, G. MUNZERT (Muenster; Biberach, Germany) ........................................................................................................... 4233

Serum Levels of CA15-3, KL-6 and BCA225 Are Positively Correlated with Each Other in the General Population. G. RI, S. OHNO, T. YAMAMOTO, E. ITO, M. FURUTANI, Y. FURUTANI, Y. UMEEDA, T. TSUKAHARA, N. HAGITA, R. MATSUOKA (Tokyo, Japan) ........................................................................................................... 4239


Contents continued on the preceding page
Estimation of Relationship Between Descriptors and Cytotoxicity of Newly Synthesized 1,2,3,4-Tetrahydroisoquinoline Derivatives. M. ISHIHARA, H. HATANO, F. TAKEKAWA, M. KAWASE, H. SAKAGAMI (Saitama; Ehime, Japan) ................................................................. 4077

Clinical Studies

Phase I/II Study of PHY906/Capcitabine in Advanced Hepatocellular Carcinoma. Y. YEN, S. SO, M. ROSE, M.W. SAIF, E. CHU, S.-H. LIU, A. FOO, Z. JIANG, T. SU, Y.-C. CHENG (Duarte; Stanford, CA; West Haven; New Haven, CT, USA) ................................................................. 4083


Clinicopathological Significance of Sip1-associated Epithelial Mesenchymal Transition in Non-small Cell Lung Cancer Progression. N. MIURA, T. YANO, F. SHOJI, D. KAWANO, T. TAKENAKA, K. ITO, Y. MORODOMI, I. YOSHINO, Y. MAEHARA (Fukuoka; Chiba, Japan) ................................................................. 4099

* Review: Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy. G. TING, C.-H. CHANG, H.-E. WANG (Miaoli; Taoyuan; Taipei, Taiwan, ROC) ................................................................. 4107


Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy. P. PILATI, E. MAMMANO, S. MOCELLIN, E. TESSARI, M. LISE, D. NITTI (Padova, Italy) ................................................................. 4139

“Glassy” Cells in Barrett’s Mucosa. C.A. RUBIO (Stockholm, Sweden) ................................................................. 4145

Conservative Management of Low-grade Endometrial Stromal Sarcoma Followed by Pregnancy and Severe Recurrence. M. KOSKAS, P. MORICE, C. YAZBECK, P. DUVILLARD, F. WALKER, P. MADELENAT (Paris; Villejuif, France) ................................................................. 4147

Relationships of P53 and Bak with EPO and EPOR in Human Colorectal Cancer. M. BALTAZIAK, M. KODA, A. WINCEWICZ, M. SULKOWSKA, L. KANCZUGA-KODA, S. SULKOWSKI (Bialystok, Poland) ................................................................. 4151

S100A8 and S100A9 Expression Is a Crucial Factor for Dedifferentiation in Thyroid Carcinoma. Y. ITO, K. ARAI, R. NOZAWA, H. YOSHIDA, M. HIROKAWA, M. FUKUSHIMA, H. INOUE, C. TOMODA, M. KIHARA, T. HIGASHIYAMA, Y. TAKAMURA, A. MIYA, K. KOBAYASHI, F. MATSUZUKA, A. MIYAUCHI (Kobe; Shizuoka, Japan) ................................................................. 4157


Contents continued on the preceding page


Doxycycline Induces Apoptosis in PANC-1 Pancreatic Cancer Cells. K. SON, S. FUJIOKA, T. IIDA, K. FURUKAWA, T. FUJITA, H. YAMADA, P.J. CHIAO, K. YANAGA (Tokyo, Japan; Houston, TX, USA) ............... 3995

Molecular Imaging Application of Radiiodinated Anti-EGFR Human Fab to EGFR-overexpressing Tumor Xenografts. N. XI, D. CAI, W. YE, X. WANG, Y. LI, P. ZHAO, A. ZHANG, R. ZHANG, B. CAO (Jiangsu, P.R. China; Grand Rapids, MI, USA) .................................................................................................................. 4005

MG-63 Osteoblast-like Cells Enhance the Osteoprotegerin Expression of PC-3 Prostate Cancer Cells. H. KATOPDIS, A. PHILIPPOU, R. TENTA, C. DOILLON, K.K. PAPACHRONI, A.G. PAPAVASSILIOU, M. KOUTSILIERIS (Athens, Greece; Quebec, QC, Canada) .................................................................................................................. 4013

HER2 Status on Persistent Disseminated Tumor Cells after Adjuvant Therapy May Differ from Initial HER2 Status on Primary Tumor. N. KRAWCZYK, M. BANYS, H. NEUBAUER, E.-F. SOLOMAYER, C. GALL, M. HAHN, S. BECKER, R. BACHMANN, D. WALLWIENER, T. FEHM (Tuebingen, Germany) .............. 4019

Targeting CWR22Rv1 Prostate Cancer Cell Proliferation and Gene Expression by Combinations of the Phytochemicals EGCG, Genistein and Quercetin. T.-C. HSIEH, J.M. WU (Valhalla, NY, USA) ................. 4025

Expression of L1 Cell Adhesion Molecule Is a Significant Prognostic Factor in pT3-stage Gastric Cancer. Y. KODERA, H. NAKANISHI, S. ITO, K. MISAWA, Y. ITO, G. NAKAYAMA, M. KOIKE, M. FUJIWARA, Y. YAMAMURA, A. NAKAO (Aichi, Japan) .................................................................................................................. 4033

192R Allele of Paraoxonase 1 (PON1) Gene as a New Marker for Susceptibility to Bladder Cancer. Ö. ÖZTÜRK, Ö.F. KAĞNICI, T. ÖZTÜRK, H. DURAK, B.M. TÜZÜNER, H.I. KISAKESEN, Ç. ÇAKALIR, T. İSBİR (Istanbul, Turkey) .................................................................................................................. 4041

Mutations of LKB1 Gene in Pancreatic Ductal Adenocarcinomas Induced by N-Nitrosobis(2-oxopropyl)amine in Hamsters. M. FURUKAWA, A. YAMASAKI, J. YOSHIDA, M. TSUJINO, N. WAKABAYASHI, K. HONOKI, T. TSUJIUCHI (Osaka; Nara, Japan) .................................................................................................................. 4047

In Vivo Model of Pseudomyxoma Peritonei for Novel Candidate Drug Discovery. T.C. CHUA, J. AKHER, P. YAO, D.L. MORRIS (Sydney, NSW, Australia) .......................................................... 4051

Expression and Mutational Status of PDGFR in Thymic Tumours. M. MEISTER, P. KAHL, T. MULEY, A. MORRESI-HAUF, C. SEBENING, M.A. KERN, M. BREINIG, P. SCHNABEL, H. DIENEMANN, P. SCHIRMACHER, R.J. RIEKER (Heidelberg; Bonn; Gauting, Germany; Innsbruck, Austria) .......................................................... 4057


Rapid Induction of P-Glycoprotein mRNA and Protein Expression by Cytarabine in HL-60 Cells. M. PRENKERT, B. UGGLA, E. TINA, U. TIDEFELT, H. STRID (Örebro; Stockholm, Sweden) .................................................................................................................. 4071

Contents continued on the preceding page


Clusterin Overexpression and Relapse-free Survival in Breast Cancer. C.K. YOM, H.-Y. WOO, S.Y. MIN, S.Y. KANG, H.S. KIM (Seoul, South Korea) ................................................................. 3909

PTP4A3 Expression Increases Strongly in Lymph Node Metastases from Colorectal Carcinoma. K. GUZIŃSKA-USTYMOWICZ, A. PRYCZYNICZ, A. KEMONA (Białystok, Poland) ................................................................. 3913


Effects of 5-FU on DNA Synthesis and Cytotoxicity of Human Lymphocytes Induced by IL-2, TGF-β3 and PGE2. A. EISENTHAL, K. EYTAN, E. BRAZOWSKI, G. GITSTEIN, R. GREENBERG, Y. SKORNICK (Tel Aviv, Israel) ................................................................. 3925

Cisplatin and Oxaliplatin Cytotoxic Effects in Sensitive and Cisplatin-resistant Human Cervical Tumor Cells: Time and Mode of Application Dependency. L. MARTELLI, E. RAGAZZI, F. DI MARIO, M. BASATO, M. MARTELLI (Padova; Parma, Italy) ................................................................. 3931

CDK10 Is Not a Target for Aberrant DNA Methylation in Breast Cancer. G. HELLER, B. ZIEGLER, A. BRANDSTETTER, S. NOVAK, M. RUDAS, G. HENNIG, M. GEHRMANN, T. ACHT, S. ZÖCHBAUER-MÜLLER, M. FILIPITS (Vienna, Austria; Cologne, Germany) ................................................................. 3939

Frequent CDH3 Demethylation in Advanced Gastric Carcinoma. K. HIBI, Y.-H. KITAMURA, H. MIZUKAMI, T. GOTO, K. SAKURABA, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (Yokohama, Japan) ................................................................. 3945

Decreased Plasma Ghrelin Levels in Patients with Advanced Cancer and Weight Loss in Comparison to Healthy Individuals. I. LEGAKIS, J. STATHOPOULOS, T. MATZOURIDIS, G.P. STATHOPOULOS (Athens, Greece) ................................................................. 3949


Glutathione Modulation Reverses the Growth-promoting Effect of Growth Factors, Improving the 5-Fluorouracil Antitumour Response in WiDr Colon Cancer Cells. T. PALOMARES, M. CARAMÉS, I. GARCÍA-ALONSO, A. ALONSO-VARONA (Leioa, Vizcaya, Spain) ................................................................. 3957

Transition of Cleaved Notch1 and Gene Expression Changes in Myeloblastic Leukemia Cells Stimulated with Notch Ligands. L. FU, K.-I. KATSUBE, S. TOHDA (Tokyo, Japan) ................................................................. 3967

3-Dimensional Microarray Analysis of Estrogen Signal-related Genes in Breast Cancer Tissues. M. MATSUMOTO, H. SAKAMOTO, Y. YAMAGUCHI, Y. SEINO, H. TAKEI, M. KUROSUMI, H. SASANO, N. YAEGASHI, S.-I. HAYASHI (Sendai; Tokyo; Saitama, Japan) ................................................................. 3971


Contents continued on the preceding page.
Potent Inhibition of Tubulin Polymerisation and Proliferation of Paclitaxel-resistant 1A9PTX22 Human Ovarian Cancer Cells by Albendazole. S.W.L. CHU, S. BADAR, D.L. MORRIS, M.H. POURGHOLAMI (Sydney, NSW, Australia) .......................................................... 3791

Xanthohumol Activates the Proapoptotic Arm of the Unfolded Protein Response in Chronic Lymphocytic Leukemia. S. LUST, B. VANHOECKE, M. VAN GELE, J. BOELENS, H. VAN MELCKEBEKE, M. KAILÈ, W.V. BERGOE, G. HAEGERMAN, J. PHILIPPI, M. BRACKE, F. OFFNER (Ghent, Belgium) ............................. 3797

Artemisinin-Transferrin Conjugate Retards Growth of Breast Tumors in the Rat. H. LAI, I. NAKASE, E. LACOSTE, N.P. SINGH, T. SASAKI (Seattle, WA, USA) .............................................................................. 3807


Down-regulation of 20-HETESynthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth. A. ALEXANIAN, V.A. RUFANOVA, B. MILLER, A. FLASCH, R.J. ROMAN, A. SOROKIN (Milwaukee, WI, USA) .................................................................................................................. 3819

Tetraidothyroacetic Acid (Tetrac) and Tetrac Nanoparticles Inhibit Growth of Human Renal Cell Carcinoma Xenografts. M. YALCIN, D.J. BHARALI, L. LANSING, E. DYSKIN, S.S. MOUSA, A. HERCBERGS, F.B. DAVIS, P.J. DAVIS, S.A. MOUSA (Rensselaer; Albany, NY; Cleveland, OH, USA; Bursa, Turkey) .............................................................................. 3825

* Short Review: Telomeres and Telomerase in Sarcomas. T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, M. OCHI (Hiroshima, Japan) ................................................................. 3833


Inhibitory Effect of Cordycepin on Hematogenic Metastasis of B16-F1 Mouse Melanoma Cells Accelerated by Adenosine-5'-diphosphate. N. YOSHIKAWA, M. KUNITOMO, S. KAGOTA, K. SHINOZUKA, K. NAKAMURA (Hyogo, Japan) .................................................................................................................. 3857

Expression of M-CSF and CSF-1R Is Correlated with Histological Grade in Soft Tissue Tumors. E. RICHARDSEN, S.W. SØRBYE, J.P. CROWE, J.-L. YANG, L.-T. BUSUND (Tromsø, Norway; Randwick; Sydney, NSW, Australia) ........................................................................................................ 3861

Formulation, Characterization and Evaluation of Curcumin-loaded PLGA Nanospheres for Cancer Therapy. A. MUKERJEE, J.K. VISHWANATHA (Fort Worth, TX, USA) ........................................................................................................ 3867

Infiltration by Macrophages and Lymphocytes in Transplantable Mouse Sarcoma after Irradiation with High-intensity Focused Ultrasound. S. CHIDA, K. OKADA, N. SUZUKI, C. KOMORI, Y. SHIMADA (Akita, Japan) .................................................................................................................. 3877


The Expression of MT1 Melatonin Receptor and Ki-67 Antigen in Melanoma Malignum. K. DANIELCZYK, P. DZIEGIEL (Wrocław; Poznań, Poland) ........................................................................................................ 3887

Contents continued on the preceding page